BRPI0817396C8 - composição farmacêutica para tratar deficiência de vitamina b¹² - Google Patents

composição farmacêutica para tratar deficiência de vitamina b¹²

Info

Publication number
BRPI0817396C8
BRPI0817396C8 BRPI0817396A BRPI0817396A BRPI0817396C8 BR PI0817396 C8 BRPI0817396 C8 BR PI0817396C8 BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 C8 BRPI0817396 C8 BR PI0817396C8
Authority
BR
Brazil
Prior art keywords
deficiency
vitamin
pharmaceutical composition
individual
treating
Prior art date
Application number
BRPI0817396A
Other languages
English (en)
Portuguese (pt)
Inventor
Castelli Cristina
Kragie Laura
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817396(C8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BRPI0817396A2 publication Critical patent/BRPI0817396A2/pt
Publication of BRPI0817396B1 publication Critical patent/BRPI0817396B1/pt
Publication of BRPI0817396B8 publication Critical patent/BRPI0817396B8/pt
Publication of BRPI0817396C1 publication Critical patent/BRPI0817396C1/pt
Publication of BRPI0817396C8 publication Critical patent/BRPI0817396C8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0817396A 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹² BRPI0817396C8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US60/984,898 2007-11-02
US2010808P 2008-01-09 2008-01-09
US61/020,108 2008-01-09
US8356608P 2008-07-25 2008-07-25
US61/083,566 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (5)

Publication Number Publication Date
BRPI0817396A2 BRPI0817396A2 (pt) 2015-04-07
BRPI0817396B1 BRPI0817396B1 (pt) 2019-04-24
BRPI0817396B8 BRPI0817396B8 (pt) 2020-02-04
BRPI0817396C1 BRPI0817396C1 (pt) 2020-11-17
BRPI0817396C8 true BRPI0817396C8 (pt) 2021-05-25

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817396A BRPI0817396C8 (pt) 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹²

Country Status (18)

Country Link
US (3) US8022048B2 (OSRAM)
EP (1) EP2215047B1 (OSRAM)
JP (1) JP5555634B2 (OSRAM)
KR (1) KR101344369B1 (OSRAM)
CN (1) CN101952241B (OSRAM)
AU (1) AU2008318423B2 (OSRAM)
BR (1) BRPI0817396C8 (OSRAM)
CA (1) CA2704780C (OSRAM)
CL (1) CL2010000434A1 (OSRAM)
CO (1) CO6280475A2 (OSRAM)
DK (1) DK2215047T3 (OSRAM)
ES (1) ES2443817T3 (OSRAM)
MX (1) MX2010004716A (OSRAM)
NZ (1) NZ585080A (OSRAM)
PL (1) PL2215047T3 (OSRAM)
PT (1) PT2215047E (OSRAM)
RU (1) RU2469728C2 (OSRAM)
WO (1) WO2009059188A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US20110207693A1 (en) * 2010-02-24 2011-08-25 Emisphere Technologies, Inc. Oral B12 Therapy
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
BR112020006841A2 (pt) * 2017-10-05 2020-10-06 Receptor Holdings, Inc. formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
AU2018345812A1 (en) * 2017-10-05 2020-05-14 Spoke Sciences, Inc. Herbal compositions with improved bioavailability
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU4484997A (en) * 1996-09-18 1998-04-14 Thomas F. Brennan Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
MXPA01006297A (es) * 1998-12-28 2002-06-04 Biogentec Inc Tratamiento con cianocobalamina (vitamina b12) para enfermedades alergicas.
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
DE60017888T2 (de) 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
ES2386263T3 (es) * 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
HU229613B1 (en) 2001-06-01 2014-03-28 Novartis Ag Oral administration of parathyroid hormone and calcitonin
ATE443527T1 (de) 2001-08-17 2009-10-15 Novartis Pharma Gmbh 5-cnac zur oralen verabreichung von parathormonfragmenten
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
WO2004024126A1 (en) * 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
CN100579955C (zh) 2003-04-04 2010-01-13 帝斯曼知识产权资产管理有限公司 N-烷氧基草酰丙氨酸酯的制备方法
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
JP2007525472A (ja) 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物
BRPI0412458A (pt) * 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
PL1651249T3 (pl) 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
EA013518B1 (ru) * 2004-05-06 2010-06-30 Эмисфире Текнолоджис, Инк. Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
CA2575706A1 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CN101296694A (zh) * 2005-11-04 2008-10-29 真塔公司 药物镓组合物和方法

Also Published As

Publication number Publication date
CL2010000434A1 (es) 2011-01-28
US20110293589A1 (en) 2011-12-01
JP5555634B2 (ja) 2014-07-23
BRPI0817396A2 (pt) 2015-04-07
JP2011502997A (ja) 2011-01-27
EP2215047B1 (en) 2013-11-20
RU2469728C2 (ru) 2012-12-20
EP2215047A1 (en) 2010-08-11
AU2008318423B2 (en) 2013-12-05
PL2215047T3 (pl) 2014-05-30
DK2215047T3 (da) 2014-02-03
CN101952241A (zh) 2011-01-19
CA2704780A1 (en) 2009-05-07
EP2215047A4 (en) 2010-11-10
US8288360B2 (en) 2012-10-16
WO2009059188A1 (en) 2009-05-07
ES2443817T3 (es) 2014-02-20
US8557792B2 (en) 2013-10-15
CN101952241B (zh) 2014-06-11
AU2008318423A1 (en) 2009-05-07
CA2704780C (en) 2014-06-10
KR20100126263A (ko) 2010-12-01
US8022048B2 (en) 2011-09-20
RU2010118423A (ru) 2011-12-10
NZ585080A (en) 2012-05-25
PT2215047E (pt) 2014-01-20
CO6280475A2 (es) 2011-05-20
US20130040910A1 (en) 2013-02-14
BRPI0817396B1 (pt) 2019-04-24
BRPI0817396B8 (pt) 2020-02-04
BRPI0817396C1 (pt) 2020-11-17
KR101344369B1 (ko) 2013-12-24
HK1146480A1 (en) 2011-06-10
US20100016255A1 (en) 2010-01-21
MX2010004716A (es) 2010-12-17

Similar Documents

Publication Publication Date Title
BRPI0817396C8 (pt) composição farmacêutica para tratar deficiência de vitamina b¹²
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112018068784A2 (pt) método para o tratamento de leucemia
CL2021003474A1 (es) Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
RU2008148597A (ru) Фармацевтические комбинации
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
MX358501B (es) Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello.
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
UA115250C2 (uk) Фармацевтичні комбінації
NZ701274A (en) Oral b12 therapy
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida
BR112023023715A2 (pt) Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer
BRPI0517241A (pt) composição farmacêutica, e, método para preparar a mesma
BR112018072583A2 (pt) composição farmacêutica de comprimido em comprimido estável
AR108792A1 (es) Composiciones que comprenden timolol
AR072871A1 (es) Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO AO INVENTOR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 24/04/2019 QUANTO AO PRAZO DE VALIDADE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2746 DE 22-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.